IL145772A0 - Prodrugs of thrombin inhibitors - Google Patents

Prodrugs of thrombin inhibitors

Info

Publication number
IL145772A0
IL145772A0 IL14577200A IL14577200A IL145772A0 IL 145772 A0 IL145772 A0 IL 145772A0 IL 14577200 A IL14577200 A IL 14577200A IL 14577200 A IL14577200 A IL 14577200A IL 145772 A0 IL145772 A0 IL 145772A0
Authority
IL
Israel
Prior art keywords
prodrugs
thrombin inhibitors
thrombin
inhibitors
Prior art date
Application number
IL14577200A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL145772A0 publication Critical patent/IL145772A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL14577200A 1999-04-09 2000-04-05 Prodrugs of thrombin inhibitors IL145772A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19915930 1999-04-09
DE19934123 1999-07-23
DE19947920 1999-10-06
PCT/EP2000/003009 WO2000061609A2 (de) 1999-04-09 2000-04-05 Prodrugs von thrombininhibitoren

Publications (1)

Publication Number Publication Date
IL145772A0 true IL145772A0 (en) 2002-07-25

Family

ID=27219075

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14577200A IL145772A0 (en) 1999-04-09 2000-04-05 Prodrugs of thrombin inhibitors

Country Status (18)

Country Link
US (1) US7144902B1 (de)
EP (1) EP1165601A2 (de)
JP (1) JP2002542165A (de)
KR (1) KR20010108481A (de)
CN (1) CN1355810A (de)
AU (1) AU765244B2 (de)
BG (1) BG105986A (de)
BR (1) BR0009674A (de)
CA (1) CA2370267A1 (de)
HK (1) HK1046289A1 (de)
HU (1) HUP0202401A3 (de)
IL (1) IL145772A0 (de)
NO (1) NO20014875L (de)
NZ (1) NZ515026A (de)
PL (1) PL352824A1 (de)
SK (1) SK14222001A3 (de)
TR (1) TR200102912T2 (de)
WO (1) WO2000061609A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
WO2004002985A1 (en) * 2002-06-27 2004-01-08 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
CA2525940A1 (en) * 2003-05-16 2004-11-25 National Institute For Biological Standards And Control (Nibsc) Mixture
PT1737889E (pt) 2004-10-19 2010-12-13 Lonza Ag Método para síntese de péptidos em fase sólida
AU2006243000B2 (en) * 2005-05-05 2011-05-26 Macrophage Pharma Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
AU2010330743A1 (en) * 2009-12-18 2012-07-05 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
US10081624B2 (en) * 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN106674190B (zh) * 2016-12-13 2019-05-10 台州市创源工业技术有限公司 一种2-噻吩甲胺的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
EP1049673A1 (de) 1998-01-26 2000-11-08 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren
JP2002501081A (ja) 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト トロンビンインヒビター
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
JP4489976B2 (ja) * 1999-04-09 2010-06-23 ビーエーエスエフ ソシエタス・ヨーロピア 補体プロテアーゼの低分子インヒビター

Also Published As

Publication number Publication date
WO2000061609A2 (de) 2000-10-19
EP1165601A2 (de) 2002-01-02
JP2002542165A (ja) 2002-12-10
TR200102912T2 (tr) 2002-03-21
HUP0202401A3 (en) 2003-11-28
NO20014875D0 (no) 2001-10-08
CA2370267A1 (en) 2000-10-19
WO2000061609A3 (de) 2001-03-15
WO2000061609B1 (de) 2001-04-26
BG105986A (bg) 2002-06-28
BR0009674A (pt) 2002-01-15
PL352824A1 (en) 2003-09-08
NZ515026A (en) 2003-10-31
HK1046289A1 (zh) 2003-01-03
HUP0202401A2 (en) 2002-10-28
KR20010108481A (ko) 2001-12-07
AU4115600A (en) 2000-11-14
SK14222001A3 (sk) 2002-07-02
CN1355810A (zh) 2002-06-26
US7144902B1 (en) 2006-12-05
NO20014875L (no) 2001-11-13
AU765244B2 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
IL146518A0 (en) Metalloprotease inhibitors
IL149118A0 (en) Inhibitors of neuraminidases
GB9900416D0 (en) Inhibitors
IL156064A0 (en) Vla-4 inhibitors
GB9930659D0 (en) Inhibitors of complement activation
IL145772A0 (en) Prodrugs of thrombin inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
AU2002222627A1 (en) Tak1 inhibitors
IL136139A0 (en) Thrombin inhibitors
EP1235577A4 (de) Proteaseinhibitoren
EP1153022A4 (de) Protease inhibitoren
GB0030284D0 (en) Enzyme inhibitors
GB9924522D0 (en) Enzyme inhibitors
EP1232155A4 (de) Protease inhibitoren
EP1231921A4 (de) Proteaseinhibitoren
EP1229915A4 (de) Proteasehemmer
EP1229914A4 (de) Proteasehemmer
EP1229912A4 (de) Proteaseinhibitoren
EP1233771A4 (de) Proteasehemmer
EP1161237A4 (de) Protease-inhibitoren
EP1229911A4 (de) Proteaseinhibitoren
EP1173429A4 (de) Proteaseinhibitoren
EP1351930A4 (de) Protease inhibitoren
EP1231923A4 (de) Proteaseinhibitoren
IL145670A0 (en) Prodrugs of thrombin inhibitors

Legal Events

Date Code Title Description
HP Change in proprietorship